Chicago Medical Center Shows Not all PM is High Cost


Personalized Medicine Watch
By John Russell

October 28, 2008 | Diabetes is something of a modern epidemic and there is an army of academic and biopharmaceutical researchers seeking better treatment and curative strategies. Personalized medicine approaches represent a growing portion of those efforts and in the past couple of years, the University of Chicago Medical Center has had success treating genetic-caused type 1 (T1) diabetes with PM approaches.

In fact, UCMC was able to wean more than 30 children off of insulin. The children all presented symptoms of type 1 diabetes as newborns and they also shared a “genetic mutation that, by altering the function of a potassium channel involved in glucose sensing, mimics insulin-dependent diabetes. The damage caused by the mutation can be repaired by giving the children a common, inexpensive, oral drug used to treat type-2 diabetes.”

Part of what interesting here—beyond the obvious benefits of the treatment—is the low cost of treatment and the further demonstration that what we see as “diabetes” may constitute a wider variety of illnesses, perhaps many based on mutations. The developer of this therapy is reportedly an English physician named Andrew Hattersley, of Peninsula University, who focused on these genetically triggered versions of diabetes in the early 2000s.

Until recently this approach gained little attention in the U.S. UCMC’s success produced more publicity and referrals. “An interesting sidelight is that by genetic testing of children with very early onset diabetes, the team has found several other diabetes-causing mutations, although so far no immediately treatable ones,” according to the report. “Some have tiny alterations of their insulin genes. Other forms of monogenic diabetes that can masquerade as either type 1 or type 2, some of them discovered at the University of Chicago, also remain under-diagnosed.”

It seems likely we will uncover more genomic mutations whose symptoms “mimic” other diseases which we thought were well-characterized. It also seems likely that a fair number will be treatable with simple, inexpensive regimens. Write to John_Russell@bio-itworld.com with your thoughts on the opportunities and challenges associated with personalized medicine.

Related Links:

Personalized Medicine for Monogenic Diabetes

The Gene Genie 

DNA for All to See

GINA Review

Medical Genetics: Are We Ready to Get Personal with Diagnosis and Treatments?

 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

SGI and Intel
HPDA for Personalized Medicine
Sponsored by SGI and Intel


Sinequa
Turning Data Into Insight: Cognitive Search & Powerful Analytics for Life Sciences
Sponsored by Sinequa


Intel
Transforming Large Scale Genomics and Collaborative Research
Sponsored by Intel


Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.